CLINICAL & PIPELINE·Drug Approval
Accord Healthcare Secures FDA Approval for Zoledronic Acid ANDA205279, Intensifying Generic Competition
Accord Healthcare secured FDA approval for its Zoledronic Acid ANDA205279 on November 28, 2016, marking a significant generic entry. This approval for the intravenous injectable strengthens Accord's market position and intensifies competition for existing Zoledronic Acid suppliers. Procurement directors should leverage this to optimize sourcing strategies and drive cost efficiencies, while regulatory teams note ongoing labeling updates from Accord Healthcare.
90-Day Activity